Cold Spring Harbor Library  CSHL: Home
   Home       Services       Archives       About Us   
 
CSHL Publication List
CSHL Authors Publications
Go back to Search Mode

          
Sort by   in order
10 Article(s) on File
Page 1 of 1
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
Bell DW,
Brannigan BW,
Matsuo K,
Finkelstein DM,
Sordella R,
Settleman J,
Mitsudomi T,
Haber DA

Clin Cancer Res
  14 (13): 4079-84; Jul 1 2008  
[Abstract]
[DOI]

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
McDermott U,
Sharma SV,
Dowell L,
Greninger P,
Montagut C,
Lamb J,
Archibald H,
Raudales R,
Tam A,
Lee D,
Rothenberg SM,
Supko JG,
Sordella R,
Ulkus LE,
Iafrate AJ,
Maheswaran S,
Njauw CN,
Tsao H,
Drew L,
Hanke JH,
Ma XJ,
Erlander MG,
Gray NS,
Haber DA,
Settleman J

Proc Natl Acad Sci U S A
  104 (50): 19936-41; Dec 11 2007   PMCID: PMC2148401
[Abstract]
[DOI]

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
Mulloy R,
Ferrand A,
Kim Y,
Sordella R,
Bell DW,
Haber DA,
Anderson KS,
Settleman J

Cancer Res
  67 (5): 2325-30; Mar 1 2007  
[Abstract]
[DOI]

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Smolen GA,
Sordella R,
Muir B,
Mohapatra G,
Barmettler A,
Archibald H,
Kim WJ,
Okimoto RA,
Bell DW,
Sgroi DC,
Christensen JG,
Settleman J,
Haber DA

Proc Natl Acad Sci U S A
  103 (7): 2316-21; Feb 14 2006  
[Abstract]
[DOI]

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
Bell DW,
Gore I,
Okimoto RA,
Godin-Heymann N,
Sordella R,
Mulloy R,
Sharma SV,
Brannigan BW,
Mohapatra G,
Settleman J,
Haber DA

Nat Genet
  37 (12): 1315-6; Dec 2005  
[Abstract]
[DOI] [Full Text]

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak EL,
Sordella R,
Bell DW,
Godin-Heymann N,
Okimoto RA,
Brannigan BW,
Harris PL,
Driscoll DR,
Fidias P,
Lynch TJ,
Rabindran SK,
McGinnis JP,
Wissner A,
Sharma SV,
Isselbacher KJ,
Settleman J,
Haber DA

Proc Natl Acad Sci U S A
  102 (21): 7665-70; May 24 2005   PMC1129023
[Abstract]
[DOI]

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
Haber DA,
Bell DW,
Sordella R,
Kwak EL,
Godin-Heymann N,
Sharma SV,
Lynch TJ,
Settleman J

Cold Spring Harb Symp Quant Biol
  70 (0): 419-26; 2005  
[Abstract]
[DOI]

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
Sordella R,
Bell DW,
Haber DA,
Settleman J

Science
  305 (5687): 1163-7; Aug 20 2004  
[Abstract]
[DOI] [Full Text] [PDF]

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Lynch TJ,
Bell DW,
Sordella R,
Gurubhagavatula S,
Okimoto RA,
Brannigan BW,
Harris PL,
Haserlat SM,
Supko JG,
Haluska FG,
Louis DN,
Christiani DC,
Settleman J,
Haber DA

N Engl J Med
  350 (21): 2129-39; May 20 2004  
[Abstract]
[Full Text] [PDF]

DOCK4, a GTPase activator, is disrupted during tumorigenesis
Yajnik V,
Paulding C,
Sordella R,
McClatchey AI,
Saito M,
Wahrer DC,
Reynolds P,
Bell DW,
Lake R,
van den Heuvel S,
Settleman J,
Haber DA

Cell
  112 (5): 673-84; Mar 7 2003  
[Abstract]
[DOI] [Full Text] [PDF]


Page 1 of 1

Go back to Search Mode


Last Updated: September, 2017
Most Recent Publications: Jan 13, 2015

© 2012   CSHL Library and Archives   1 Bungtown Rd.   Cold Spring Harbor, NY 11724   Library Information 516-367-6872
CSHL Home Intranet